Cargando…
Response to immunotherapy plus anti‐angiogenic agent combination challenges hepatocellular carcinoma prognostic scores
This new UHPI score identifies three groups with different prognosis, but with no clear therapeutic guidance. Moreover, this model's predictive ability is now challenged in the era of combination therapies where durable responses are more commonly observed, and where response criteria remain to...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9701464/ https://www.ncbi.nlm.nih.gov/pubmed/35819258 http://dx.doi.org/10.1002/hep4.2047 |